GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (FRA:IM8N) » Definitions » Short Interest

Insmed (FRA:IM8N) Short Interest


View and export this data going back to 2000. Start your Free Trial

What is Insmed Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Insmed's Short Interest

For the Biotechnology subindustry, Insmed's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insmed's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Short Interest distribution charts can be found below:

* The bar in red indicates where Insmed's Short Interest falls into.


;
;

Insmed Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (FRA:IM8N) » Definitions » Short Interest
Comparable Companies
BMRN INCY RPRX MRNA EXEL ASND SMMT TECH ROIV CORT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
INSM:USA 0JAV:UK
Address
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Website
https://www.insmed.com
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Insmed Headlines

No Headlines